On March 25, 2019 VBL Therapeutics (Nasdaq: VBLT), reported that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held March 29 – April 3, 2019 at Georgia World Congress Center in Atlanta, Georgia (Press release, VBL Therapeutics, MAR 25, 2019, View Source [SID1234534604]). VB-111 is a first-in-class, targeted anti-cancer gene-therapy biologic with broad potential to treat a wide range of solid tumors. In addition, the company will provide a corporate overview at the H.C. Wainwright Global Life Sciences Conference to be held April 7 – 9, 2019 at the Grosvenor House, a JW Marriott Hotel in London, UK.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) Annual Meeting – Presentation Details:
Title: Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming ‘cold’ tumors to ‘hot’ tumors
Session Category: Immunology
Session Title: Immunomodulators and Response to Therapy
Date: Wednesday Apr 3, 2019
Time: 8:00 AM – 12:00 PM Eastern Time
Session Location: Exhibit Hall B, Poster Section 24
Poster Board Number: 2
Abstract Number: 4979
HCW Global Life Sciences Conference – Presentation Details:
Date:Monday, April 8
Time: 15:40 – 16:00 BST